Universal Congenital CMV Screening: The Urgent Search for Predictive Biomarkers in Newborn Testing Programs

Photo Credit: CDC/ Dr. Feldman

Congenital cytomegalovirus (cCMV) infection represents the most common congenital infection globally, affecting approximately 1 in 200 newborns across the United States — yet it remains largely unknown to the general public and medical community alike.¹ Unlike conditions routinely included in newborn screening panels, cCMV often escapes detection despite causing more disabilities than Down syndrome, fetal alcohol syndrome, or neural tube defects combined. The consequences can be devastating: permanent hearing loss, developmental delays, cerebral palsy, vision impairment, and seizures affecting an estimated 20% of infected infants.²

As momentum builds toward universal newborn screening for cCMV — with multiple states implementing or considering screening programs — an urgent research need has emerged: identifying predictive biomarkers that can distinguish which infected newborns will develop long-term sequelae, particularly sensorineural hearing loss (SNHL), from those who will remain asymptomatic. This research challenge requires access to well-characterized biospecimens from infants with confirmed cCMV infection, paired with comprehensive longitudinal follow-up data tracking developmental and audiological outcomes.³

From study design to receipt of samples, researchers investigating congenital CMV require specimens spanning maternal-fetal transmission, neonatal diagnosis, and childhood development phases, coupled with rich genomic annotation and clinical phenotyping that transforms biospecimens into powerful predictive tools.

Understanding Congenital CMV: Epidemiology and Clinical Impact

Cytomegalovirus, a member of the herpesvirus family, establishes lifelong latent infection after primary exposure. While CMV infection in healthy adults typically causes minimal or no symptoms, primary maternal infection during pregnancy — or reactivation of latent infection — can result in vertical transmission to the developing fetus with potentially severe consequences.⁴

Epidemiology and Transmission

• Prevalence: Approximately 0.5-0.7% of all live births in the United States involve congenital CMV infection, translating to roughly 20,000-30,000 affected newborns annually. CMV seropositivity in pregnant women varies by demographic factors, exceeding 80% in some populations.⁵
• Transmission routes: Fetal infection can occur through transplacental passage of virus during primary maternal infection (highest risk), reactivation of latent maternal infection, or reinfection with a different CMV strain. Primary maternal infection, particularly in early pregnancy, carries the greatest risk of severe fetal outcomes.⁶
• Symptomatic vs. asymptomatic disease: At birth, approximately 10-15% of infected infants exhibit symptomatic cCMV disease. However, even asymptomatic infants face substantial risk of delayed-onset sequelae, particularly progressive hearing loss developing during early childhood.⁷

Long-Term Sequelae

• Sensorineural hearing loss: cCMV causes an estimated 15-20% of all moderate to profound bilateral SNHL in children, making it the leading non-genetic cause of childhood hearing loss. Hearing loss can be progressive, with some children passing newborn hearing screens only to develop late-onset or progressive SNHL months to years later.⁸
• Neurodevelopmental outcomes: Children with symptomatic cCMV face elevated risks of developmental delays, intellectual disability, cerebral palsy, vision impairment, and epilepsy. Even asymptomatic infection carries low but measurable risks of adverse neurodevelopmental outcomes.⁹
• Economic burden: Lifetime costs associated with cCMV-related disabilities exceed $4 billion annually in the United States, driven primarily by hearing loss-related expenses including educational support, assistive technology, and productivity losses.¹⁰

The Case for Universal Newborn CMV Screening

Traditional newborn screening targets conditions for which early identification enables interventions improving outcomes. For cCMV, the case for universal screening rests on several pillars.

Early Diagnosis Enables Intervention

• Antiviral therapy: Valganciclovir initiated within the first month of life in infants with moderate-to-severe symptomatic cCMV disease has demonstrated benefits in preventing hearing deterioration and improving neurodevelopmental outcomes. Early diagnosis through screening is essential for timely treatment initiation.^11,12
• Enhanced audiological monitoring: Infected infants require intensive surveillance to detect progressive or late-onset hearing loss missed by standard newborn hearing screens. Early intervention with hearing aids or cochlear implants supports language development.
• Family counseling: Diagnosis enables counseling, family planning discussions, and connection to early intervention resources.

Screening Technologies

• Saliva-based CMV testing: Dried saliva spots collected on filter paper cards provide a sensitive, non-invasive method for detecting CMV DNA in newborns and integrate with existing screening infrastructure.¹³
• Urine-based testing: PCR on urine collected within 21 days remains a gold standard for confirmation, though logistics can limit population-wide implementation.
• Targeted vs. universal screening: Some programs screen infants who fail newborn hearing tests, while universal screening identifies all infected infants regardless of symptom status.

The Biomarker Challenge: Predicting Which Babies Will Develop Sequelae

Universal cCMV screening creates an urgent challenge: distinguishing which infected newborns require intensive monitoring and potential treatment from those unlikely to develop complications. Current approaches rely on symptom status at birth, but asymptomatic infants can still develop late sequelae. This creates a critical need for predictive biomarker discovery using well-characterized biospecimens.

Candidate Biomarkers Under Investigation

Viral Load Measurements

Quantification of CMV DNA in plasma, urine, or saliva shows promise as a predictor of severity and outcomes. Higher viral loads often correlate with symptomatic disease and increased sequelae risk, though overlap exists between groups.¹⁴ Access to human plasma from newborns with documented cCMV supports validation of clinically actionable viral load thresholds.

Anti-CMV Antibody Profiles

Maternal IgG levels and epitope-specific antibody signatures may predict transmission risk and fetal protection. Maternal-infant paired serology and outcome-linked cohorts can identify protective antibody patterns.¹⁵ Human serum biobanking enables retrospective testing as new assays emerge.

Inflammatory Cytokines and Immune Markers

Neonatal cytokines (e.g., IL-6, TNF-α, IP-10), soluble mediators, and immune cell phenotypes may distinguish disease trajectories. Elevated inflammatory markers have been observed in subsets of infants who later develop SNHL.¹⁶ Longitudinal immune profiling can be supported using human PBMCs for flow cytometry, functional assays, and single-cell technologies.

Placental Biomarkers

Placental and cord blood analyses reveal transcriptomic and proteomic signatures linked to fetal outcomes. Reported multi-protein signatures may help stratify infection severity and predict neurodevelopmental outcomes.¹⁷

Host Genetic Factors

Immune-related polymorphisms may influence susceptibility, severity, and sequelae development. Genome-wide association studies require large cohorts with confirmed cCMV and validated longitudinal outcomes, supported by genomic-enabled biospecimen collections with genomic annotation.

Microbiome Signatures

Early evidence suggests neonatal microbiome composition may shape immune response to CMV and influence disease trajectories, though this remains early-stage and requires specialized sampling and analysis.¹⁸

Biospecimen Requirements for cCMV Research

Advancing congenital CMV research requires thoughtfully designed biospecimen collections that address unique diagnostic timing windows, maternal-infant pairing, and long-term sequelae monitoring.

Specimen Types and Timing

Newborn Specimens

• Saliva or urine collected within 21 days for confirmed diagnosis
• Dried blood spots from routine newborn screening
• Plasma / serum for viral load, antibody, and biomarker measurements
• Whole blood for genomic analysis and immune profiling workflows
• PBMCs for cellular immune phenotyping and functional assays

Maternal Specimens

• Prenatal serum for CMV serostatus and antibody characterization
• Delivery timepoint specimens for maternal-infant pair analysis
• Longitudinal prenatal specimens when primary infection timing is documented

Placental and Cord Blood

• Placental tissue for pathology, immunohistochemistry, and multi-omics
• Cord blood plasma for biomarker studies
• Cord blood cells for immunophenotyping

Longitudinal Follow-Up Collections

Because cCMV sequelae can be progressive and delayed, longitudinal collections throughout infancy and childhood are essential:

• 3-month intervals during the first year to track viral clearance and immune development
• Annual collections aligned with audiological assessments
• Collection at hearing loss diagnosis to evaluate contemporaneous biomarkers

Critical Clinical Annotation

Biospecimens must be paired with rigorous documentation to support predictive biomarker modeling:

Maternal History

• CMV serostatus pre-pregnancy (if known)
• Timing of seroconversion during pregnancy
• Indicators of symptomatic primary infection
• Prior pregnancies and any cCMV outcomes

Neonatal Characteristics

• Disease severity classification (asymptomatic vs. symptomatic)
• Specific clinical findings (microcephaly, hepatosplenomegaly, etc.)
• CMV viral load at diagnosis
• Gestational age and birth parameters

Outcomes Data

• Serial audiological assessments (with threshold data)
• Neurodevelopmental evaluations
• Vision assessments
• Treatment exposure (antiviral therapy)
• Timing of sequelae onset

State-Level Screening Programs: Generating Real-World Evidence

The expansion of state-mandated cCMV screening programs creates unprecedented opportunities for biospecimen-based research. States that have implemented or are piloting screening programs can generate large cohorts of identified infected infants with standardized follow-up, enabling:

• Large, population-based cohorts: inclusive of asymptomatic infections, improving generalizability
• Standardized diagnosis: consistent algorithms reduce heterogeneity
• Structured follow-up: mandated audiology monitoring improves outcome data quality
• Real-world treatment patterns: observational evidence complements trial data

Biobanking partnerships with screening programs ensure specimens are collected, processed, and stored appropriately for future research while maintaining regulatory and ethical compliance.

Supporting cCMV Research Through Biospecimen Services

Given the complexity of congenital infection research, access to prospective biospecimen collection services is essential. Custom collections can be designed to:

• Enroll mother-infant pairs across the United States during pregnancy or at delivery
• Implement standardized specimen collection protocols aligned with research objectives
• Coordinate longitudinal follow-up collections aligned with developmental milestones
• Link biospecimens with comprehensive clinical data and outcome measures
• Ensure appropriate consent processes for pediatric research

From study design to receipt of samples, streamlined processes enable investigators to focus on scientific questions while biospecimen experts manage recruitment, logistics, processing, storage, and shipping.

For researchers requiring existing inventory, curated collections of congenital infection biospecimens can support immediate study initiation. Explore options through our infectious disease biospecimen portfolio, or contact our team to discuss cCMV cohort requirements.

The Path Forward: Precision Medicine for Congenital CMV

The goal of precision medicine for cCMV is clear: accurately predict which infected newborns require intensive intervention versus supportive care alone, preventing unnecessary treatment while ensuring no at-risk child is missed. Achieving this vision requires:

• Multimodal biomarker panels: integrating viral, immunological, genetic, and clinical markers into validated prediction models
• Prospective validation studies: large, diverse cohorts with longitudinal outcome capture
• Implementation research: translating biomarkers into screening-compatible assays
• Economic modeling: demonstrating cost-effectiveness of biomarker-guided pathways
• Therapeutic development: identifying new targets beyond current antiviral approaches

Conclusion

Universal newborn screening for congenital CMV represents an imminent paradigm shift in pediatric infectious disease management, with potential to prevent thousands of cases of hearing loss and developmental disability annually. However, realizing this potential requires solving the biomarker challenge: distinguishing which infected infants face highest risks and will benefit most from intervention.

This research imperative demands robust biospecimen resources — newborn specimens with confirmed cCMV, maternal specimens characterizing prenatal infection, placental specimens revealing fetal responses, and longitudinal collections tracking natural history. When paired with comprehensive clinical phenotyping and outcome data, these specimens become powerful tools for discovery and validation of predictive biomarkers that can guide clinical decision-making for generations of affected children.

Learn more about our CMV biospecimen portfolio or contact our team to discuss biospecimen needs for congenital CMV research.

---

References (AMA Style)

1. CDC. Congenital Cytomegalovirus (cCMV) Infection and Disease 2024 Case Definition. Centers for Disease Control and Prevention. Published 2024. Accessed December 9, 2024.
2. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86-102. doi:10.1128/CMR.00062-12
3. The Urgent Search for Predictive Biomarkers in the Emerging Era of Universal Congenital Cytomegalovirus Screening. 2024. PMID: 41194669.
4. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202-213. doi:10.1002/rmv.655
5. Boppana SB, Ross SA, Fowler KB. Congenital cytomegalovirus infection: clinical outcome. Clin Infect Dis. 2013;57 Suppl 4(Suppl 4):S178-S181. doi:10.1093/cid/cit629
6. Ornoy A, Diav-Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol. 2006;21(4):399-409. doi:10.1016/j.reprotox.2005.02.002
7. Fowler KB, Boppana SB. Congenital cytomegalovirus infection. Semin Perinatol. 2018;42(3):149-154. doi:10.1053/j.semperi.2018.02.002
8. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol. 2008;41(2):57-62. doi:10.1016/j.jcv.2007.09.004
9. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355-363. doi:10.1002/rmv.544
10. Grosse SD, Dollard SC, Ross DS, Cannon M. Newborn screening for congenital cytomegalovirus: options for hospital-based and public health programs. J Clin Virol. 2009;46 Suppl 4(Suppl 4):S32-S36. doi:10.1016/j.jcv.2009.09.005
11. Kimberlin DW, Jester PM, Sánchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372(10):933-943. doi:10.1056/NEJMoa1404599
12. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;17(6):e177-e188. doi:10.1016/S1473-3099(17)30143-3
13. Boppana SB, Ross SA, Shimamura M, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med. 2011;364(22):2111-2118. doi:10.1056/NEJMoa1006561
14. Lanari M, Lazzarotto T, Venturi V, et al. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics. 2006;117(1):e76-e83. doi:10.1542/peds.2005-0629